Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A Review.

Abstract:

PURPOSE:This article outlines several important issues regarding the management of patients with gout. The topics discussed include best practices for gout based on the most current guidelines, opportunities for improving gout management, and current and emerging therapies for gout. METHODS:[PubMed and Google Scholar databases] were search for all articles and trials published before 2016, using the key terms [hyperuricemia, gout, tophi, joint erosion, joint damage, treatment guidelines, American College of Rheumatology (ACR), European League Against Rheumatism (EULAR), flare, comorbidity, epidemiology, adherence, serum uric acid (sUA), monosodium urate (MSU), <6 mg/dL, MSU crystal formation, as well as individual drug names and classes of treatments of interest (allopurinol, febuxostat, colchicine, non-steroidal anti-inflammatories (NSAIDs)]. Studies were selected that presented data on gout treatment, including drugs under development, and on the management of gout from both the physician and patient perspectives. The reference lists of identified articles were searched manually for additional publications. FINDINGS:Gout, a progressive debilitating form of inflammatory arthritis, is caused by factors that elevate serum uric acid (sUA) levels, leading to hyperuricemia. Continued elevated sUA can result in monosodium urate crystal deposition in joints and soft tissues, causing acute and chronic inflammation. Crystal deposition can lead to chronic gout, with an increased number of flares, tophi development, and structural joint damage. The aims of gout treatment are to reduce the sUA level to <6 mg/dL, to inhibit the formation of new crystals, and to promote the dissolution of existing crystals. Gout is often poorly managed for several reasons, including a lack of adherence to treatment guidelines by health care providers, patients' poor adherence to therapy, and differences between a provider's and patient's perspectives regarding treatment. IMPLICATIONS:Patients need to be educated about their diagnosis and management of the disease, such as the importance of compliance with long-term treatment. Gout treatment may also confounded by contraindications to current standards of therapy and the limitations of current treatment paradigms. Recently approved medications, as well as drugs under development, may provide new ways for reaching the sUA target and also "curing" the disease.

journal_name

Clin Ther

journal_title

Clinical therapeutics

authors

Keenan RT

doi

10.1016/j.clinthera.2016.12.011

subject

Has Abstract

pub_date

2017-02-01 00:00:00

pages

430-441

issue

2

eissn

0149-2918

issn

1879-114X

pii

S0149-2918(16)30924-9

journal_volume

39

pub_type

杂志文章,评审
  • Comparative Bioavailability of Hydroxyprogesterone Caproate Administered via Intramuscular Injection or Subcutaneous Autoinjector in Healthy Postmenopausal Women: A Randomized, Parallel Group, Open-label Study.

    abstract:PURPOSE:The purpose of this study was to evaluate the bioavailability of hydroxyprogesterone caproate (HPC) administered as a subcutaneous injection in the back of the upper arm using a prefilled autoinjector syringe with a 27-gauge needle compared with standard intramuscular injection in the gluteus maximus using a 21...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.clinthera.2017.10.020

    authors: Krop J,Kramer WG

    更新日期:2017-12-01 00:00:00

  • Pharmacokinetics of oral cyanocobalamin formulated with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC): an open-label, randomized, single-dose, parallel-group study in healthy male subjects.

    abstract:BACKGROUND:Vitamin B12 (cobalamin) deficiency may be caused by inadequate dietary intake of B12 or by conditions that result in malabsorption of the vitamin. Crystalline vitamin B12, usually in the form of cyanocobalamin, is administered parenterally (ie, intramuscularly) or orally for treating deficiency states. Intra...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.clinthera.2011.05.088

    authors: Castelli MC,Wong DF,Friedman K,Riley MG

    更新日期:2011-07-01 00:00:00

  • Comparison of a salicylic acid cleanser and a benzoyl peroxide wash in the treatment of acne vulgaris.

    abstract::A four-week crossover study to compare the efficacy of an acne cleanser containing 2% salicylic acid with that of a 10% benzoyl peroxide wash was conducted in 30 patients with acne vulgaris. The results demonstrated that only patients treated with the salicylic acid cleanser had a significant reduction in comedones. P...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:

    authors: Shalita AR

    更新日期:1989-03-01 00:00:00

  • Developing a uniform reporting system for preventable adverse drug events.

    abstract::The United States Pharmacopeia (USP) Practitioners' Reporting Network utilized nearly three decades of experience to design and develop a nationwide, anonymous, Internet-accessible service for hospitals to report and benchmark medication errors (also known as "preventable adverse drug events"). As nationwide experient...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/s0149-2918(98)80008-8

    authors: Cousins DD

    更新日期:1998-01-01 00:00:00

  • The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model.

    abstract::This study compared the cost-effectiveness of donepezil, a new cholinesterase inhibitor indicated for the treatment of mild-to-moderate probable Alzheimer's disease (AD), with no treatment. A Markov state transition model was employed to simulate treatment costs based on Swedish epidemiologic data. The Markov states u...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/S0149-2918(00)80025-9

    authors: Jönsson L,Lindgren P,Wimo A,Jönsson B,Winblad B

    更新日期:1999-07-01 00:00:00

  • Aripiprazole in schizophrenia and schizoaffective disorder: A review.

    abstract:BACKGROUND:During the past decade, there has been some progress in the pharmacotherapy of schizophrenia and schizoaffective disorder. Current evidence supports the use of various second-generation, or atypical, antipsychotic medications, although few of these agents have been associated with long-term efficacy and tole...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2010.01.021

    authors: Stip E,Tourjman V

    更新日期:2010-01-01 00:00:00

  • Short-term Safety, Tolerability, and Pharmacokinetics of MRX-I, an Oxazolidinone Antibacterial Agent, in Healthy Chinese Subjects.

    abstract:PURPOSE:This study was designed to evaluate the safety and pharmacokinetic profiles of MRX-I tablet, an oxazolidinone antibacterial agent, in healthy Chinese subjects. METHODS:The study was composed of 3 sequential periods. Period 1 was a randomized, double-blind, placebo-controlled, sequential ascending dose (50 to 1...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.clinthera.2017.12.017

    authors: Wu X,Li Y,Zhang J,Zhang Y,Yu J,Cao G,Chen Y,Guo B,Shi Y,Huang J,Cao Y,Liu X,Wu J,Gordeev MF,Yuan H,Wang W

    更新日期:2018-02-01 00:00:00

  • Efficacy and Tolerability of Combination Therapy Versus Monotherapy with Candesartan and/or Amlodipine for Dose Finding in Essential Hypertension: A Phase II Multicenter, Randomized, Double-blind Clinical Trial.

    abstract:PURPOSE:Intensive blood pressure (BP) lowering is important for the treatment of hypertension; however, it has been a challenge to achieve target BP in many patients. The purpose of this study was to explore the optimal dosage of a fixed-dose combination of candesartan cilexetil (CAN) and amlodipine besylate (AML), by ...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.clinthera.2017.06.014

    authors: Sohn IS,Kim CJ,Ahn T,Youn HJ,Jeon HK,Ihm SH,Cho EJ,Chung WB,Chae SC,Kim WS,Nam CW,Park SM,Choi JY,Kim YK,Hong TJ,Lee HY,Cho JH,Shin ES,Yoon JH,Yang TH,Jeong MH,Lee JH,Park JI

    更新日期:2017-08-01 00:00:00

  • Comparing Outcomes Between Thiazide Diuretics and Other First-line Antihypertensive Drugs in Long-term Nursing Home Residents.

    abstract:PURPOSE:Hypertension occurs in >50% of US nursing home (NH) residents, but it is unclear which antihypertensive classes offer the best balance of benefits and risks in this population. The objectives of this study were to describe the patterns of antihypertensive medication treatment in this population, focusing on thi...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2020.02.016

    authors: Boockvar KS,Song W,Lee S,Intrator O

    更新日期:2020-04-01 00:00:00

  • Inhaled dry powder insulin for the treatment of diabetes mellitus.

    abstract:BACKGROUND:Inhaled dry powder insulin (IDPI) is the first inhaled insulin approved for the treatment of type 1 and type 2 diabetes mellitus (DM). OBJECTIVE:This article reviews available information on IDPI, focusing on its clinical pharmacokinetics, comparative efficacy, tolerability, adverse events, dosage and admin...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2007.05.015

    authors: Setter SM,Levien TL,Iltz JL,Odegard PS,Neumiller JJ,Baker DE,Campbell RK

    更新日期:2007-05-01 00:00:00

  • Potential Etiologic Factors of Microbiome Disruption in Autism.

    abstract:PURPOSE:The primary purpose of this article was to consider the candidate disruptors of the development of a healthy microbiome in patients with autism. The reported abnormalities in the microbiome of individuals with autism are discussed. METHODS:This selected review used data from published articles related to the a...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2015.04.001

    authors: Buie T

    更新日期:2015-05-01 00:00:00

  • Finding Truth in a World Full of Spin: Myth-Busting in the Case of Sovaldi.

    abstract:PURPOSE:Public discourse regarding the hepatitis C virus (HCV) drug Sovaldi® (sofosbuvir) has become inflamed, generating much heat but little light concerning the clinical, health economic, and quality-of-life merits of Sovaldi®. The purpose of this article is to provide a factual basis for evaluating the claims regar...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2015.02.009

    authors: Schiff L

    更新日期:2015-05-01 00:00:00

  • Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion.

    abstract::The pharmacodynamic parameter that appears to correlate best with a successful therapeutic outcome with beta-lactam antibiotics is the length of time the serum antibiotic concentration remains above the minimum inhibitory concentration (MIC) for the infecting pathogen. By maximizing this parameter, continuous administ...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/S0149-2918(00)86736-3

    authors: Burgess DS,Summers KK,Hardin TC

    更新日期:1999-11-01 00:00:00

  • Determinants of antipyretic misuse in children up to 5 years of age: a cross-sectional study.

    abstract:BACKGROUND:Fever in children is a common and usually benign symptom. It is known that antipyretic treatment is ineffective in the prevention of simple febrile seizures. Caregivers' administration of antipyretic medications to children has been reported, but data concerning the formulations used, actual doses administer...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2006.05.010

    authors: Bilenko N,Tessler H,Okbe R,Press J,Gorodischer R

    更新日期:2006-05-01 00:00:00

  • A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.

    abstract:BACKGROUND:Oxymorphone extended release (ER) is a tablet formulation of the mu-opioid agonist oxymorphone designed to achieve a low peak-to-trough fluctuation in plasma concentrations over a 12-hour dosing period. OBJECTIVE:This study compared the analgesic efficacy, dose response, and tolerability of 3 doses of oxymo...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.clinthera.2006.03.008

    authors: Kivitz A,Ma C,Ahdieh H,Galer BS

    更新日期:2006-03-01 00:00:00

  • Integrins: Integrating the Biology and Therapy of Cell-cell Interactions.

    abstract:PURPOSE:Although the role of integrins has been described in a variety of diseases, these roles seem to be distinct. To date, no study has attempted to provide links to the various pathways by which such integrins can be involved in these diverse disease settings. The purpose of this review was to address this gap in o...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2017.11.002

    authors: Pandolfi F,Franza L,Altamura S,Mandolini C,Cianci R,Ansari A,Kurnick JT

    更新日期:2017-12-01 00:00:00

  • Lessons learned with ambulatory blood pressure monitoring: a focus on ramipril.

    abstract::Ambulatory blood pressure monitoring (ABPM) has been available since the mid-1970s. Widespread use of ABPM in research settings has led to an appreciation of its advantages and disadvantages. ABPM is a valuable research tool because of its ability to evaluate the duration and consistency of action with new antihyperte...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:

    authors: Burris JF

    更新日期:1993-05-01 00:00:00

  • Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study.

    abstract:BACKGROUND:Alendronate, an oral bisphosphonate, is available for the treatment of osteoporosis in a 70-mg once-weekly and a 10-mg once-daily formulation. OBJECTIVES:This study aimed to determine patient preference for once-weekly versus once-daily dosing with alendronate, and to determine which treatment regimen the p...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1016/s0149-2918(02)80085-6

    authors: Simon JA,Lewiecki EM,Smith ME,Petruschke RA,Wang L,Palmisano JJ

    更新日期:2002-11-01 00:00:00

  • Efficacy and tolerability of lovastatin in hypercholesterolemic women.

    abstract::In a previous report of a multicenter study (Kannel et al, 1990), the results of 6 months' treatment with lovastatin in 489 adults with primary hypercholesterolemia were presented. The present report contains the results from the 236 women patients. The intial dose of lovastatin was 20 mg daily and could be increased ...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章,多中心研究

    doi:

    authors: D'Agostino RB,Kannel WB,Stepanians MN,D'Agostino LC

    更新日期:1992-05-01 00:00:00

  • Economic assessment of ketorolac versus narcotic analgesics in postoperative pain management.

    abstract::The medical records for 174 patients who underwent cholecystectomy (n = 52) or hip/knee replacement (n = 122) at four community-based medical centers were retrospectively reviewed to determine if using a nonnarcotic alternative to morphine sulfate and/or meperidine as a primary postoperative analgesic could reduce res...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,多中心研究

    doi:

    authors: Trotter JP,Reinhart SP,Katz RM,Glazier HS

    更新日期:1993-09-01 00:00:00

  • Comparison of Murraya koenigii- and Tribulus terrestris-based oral formulation versus tamsulosin in the treatment of benign prostatic hyperplasia in men aged >50 years: a double-blind, double-dummy, randomized controlled trial.

    abstract:BACKGROUND:Drug treatment can defer surgical intervention in benign prostatic hyperplasia (BPH), a common disorder in elderly men, and is widely practiced. Various herbal formulations have been used for the treatment of BPH, but few have been compared with established modern medicines in head-to-head clinical trials. ...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.clinthera.2011.11.005

    authors: Sengupta G,Hazra A,Kundu A,Ghosh A

    更新日期:2011-12-01 00:00:00

  • Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.

    abstract:BACKGROUND:Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) with activity against both wild-type HIV and viruses harboring NNRTI resistance. Etravirine is mainly eliminated via the hepatobiliary route. OBJECTIVES:This study in HIV- patients with mild or moderate hepatic impairment and healthy mat...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2010.02.013

    authors: Schöller-Gyüre M,Kakuda TN,De Smedt G,Woodfall B,Berckmans C,Peeters M,Hoetelmans RM

    更新日期:2010-02-01 00:00:00

  • The financial impact of OBRA-90 on community pharmacies: an overview.

    abstract::The Omnibus Budget Reconciliation Act of 1990 (OBRA-90) may be the most significant piece of legislation affecting the practice of pharmacy since the Durham-Humphrey amendments to the Food, Drug and Cosmetic Act. As part of the OBRA-90 legislation, the Health Care Financing Administration (HCFA) was required to publis...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:

    authors: Nightengale B,Reeder CE

    更新日期:1993-05-01 00:00:00

  • Telbivudine for the management of chronic hepatitis B virus infection.

    abstract:BACKGROUND:Telbivudine (LdT) is an L-nucleoside that is structurally related to lamivudine. It is highly selective for hepatitis B virus (HBV) and inhibits viral DNA synthesis. LdT was approved by the US Food and Drug Administration on October 25, 2006, for the treatment of chronic HBV infection in adults who have acti...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2007.12.032

    authors: Matthews SJ

    更新日期:2007-12-01 00:00:00

  • Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.

    abstract:BACKGROUND:Biosimilars are defined as biologic products that are highly similar to reference products, notwithstanding minor differences in clinically inactive components, with no clinically meaningful differences between the biologic product and the reference product in terms of safety profile, purity, and potency. Du...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2011.12.005

    authors: Ahmed I,Kaspar B,Sharma U

    更新日期:2012-02-01 00:00:00

  • Ofloxacin in the treatment of typhoid fever resistant to chloramphenicol and amoxicillin.

    abstract::Twenty-five patients with typhoid fever, who were resistant to amoxicillin and chloramphenicol, were successfully treated with ofloxacin. Ofloxacin was administered at a dosage of 200 mg three times daily for 7 to 10 days. In a few seriously ill patients, a dosage of 400 mg three times daily for 3 days, followed by 20...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章

    doi:

    authors: Khan MA,Hayat Z,Sadick A

    更新日期:1994-09-01 00:00:00

  • Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.

    abstract:BACKGROUND:Apixaban (5 mg BID), dabigatran (available as 150 mg and 110 mg BID in Europe), and rivaroxaban (20 mg once daily) are 3 novel oral anticoagulants (NOACs) currently approved for stroke prevention in patients with atrial fibrillation (AF). OBJECTIVE:The objective of this study was to evaluate the cost-effect...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2013.12.011

    authors: Lip GY,Kongnakorn T,Phatak H,Kuznik A,Lanitis T,Liu LZ,Iloeje U,Hernandez L,Dorian P

    更新日期:2014-02-01 00:00:00

  • Postmarketing survey of the effects of an atenolol/chlorthalidone combination in the treatment of hypertension.

    abstract::A large-scale postmarketing survey was conducted in the United States to evaluate the antihypertensive efficacy and safety of a combination of 50 mg of the long-acting cardioselective beta-blocker atenolol and 25 mg of the monosulfonamyl diuretic chlorthalidone. The program included 28,585 patients (of whom 26,892 pro...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:

    authors: Maxwell MH,Garrett BN,Saunders E,Schnaper H

    更新日期:1987-01-01 00:00:00

  • Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.

    abstract:OBJECTIVES:This study was conducted to estimate the prevalence of antipsychotic polypharmacy among fee-for service state Medicaid beneficiaries initiating antipsychotic drug therapy and to investigate psychiatric and demographic predictors of such polypharmacy. METHODS:This was a retrospective cohort study employing M...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2007.01.002

    authors: Morrato EH,Dodd S,Oderda G,Haxby DG,Allen R,Valuck RJ

    更新日期:2007-01-01 00:00:00

  • Single-pill Combination Therapy of Azilsartan Medoxomil/Chlorthalidone for Treatment of Hypertension: A Systematic Review.

    abstract:PURPOSE:The goal of this study was to review recent clinical studies of azilsartan medoxomil (AZL-M) and chlorthalidone (CLD), a combined angiotensin receptor blocker and thiazide-like diuretic, and its role in recently published guidelines. This review explores the role of AZL-M/CLD in treating patients with hypertens...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2020.05.015

    authors: Kwon A,Kim GH

    更新日期:2020-07-01 00:00:00